Trials / Completed
CompletedNCT00425035
Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
A Two-part, Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of ABX-EGF in Patients With Renal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (planned)
- Sponsor
- Amgen · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
Multicenter, 2-part, multiple-dose study designed to evaluate the safety and effectiveness of weekly administration of panitumumab in subjects with renal carcinoma. Part 1 was initiated in 2001 and will not be presented here. Part 2 was designed to examine a dose of 2.5 mg/kg/wk in 2 cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panitumumab (ABX-EGF) |
Timeline
- Start date
- 2003-02-01
- First posted
- 2007-01-22
- Last updated
- 2013-05-13
Source: ClinicalTrials.gov record NCT00425035. Inclusion in this directory is not an endorsement.